Background U.S. population estimates of atherosclerotic cardiovascular disease (ASCVD) risk reduction from comprehensive cardiometabolic risk factor control remain limited among patients with ASCVD and diabetes mellitus (DM). Objectives The objective of the study was to predict 3-year reduction in composite ASCVD event...
H. Karthikeyan, Wen-Jun Fan, Ran Jin et al.· JACC: Advances· 0 citations
Background:
Prior studies demonstrate persistent race and ethnic disparities in lipid-lowering therapy (LLT) utilization among patients with prior ischemic events. These disparities may be more pronounced in a high cardiovascular (CV) risk population without prior myocardial infarction (MI) or stroke where patients...
S. Sakhuja, Q. Chan, Corinne Brooks et al.· Circulation· 0 citations
Women at high cardiovascular risk consistently experienced less intensive lipid management and LDL-C goal achievement compared with men, highlighting similar sex differences in risk factors and lipid management across regions and underscore the need for targeted strategies to improve implementation of guideline-directe...
Q. Chan, J. Cegla, J. Cornel et al.· European Heart Journal· 0 citations
In this large, global, real-world study, most patients with CAD at risk of a first MACE were undertreated with LLT and did not achieve recommended LDL-C levels, highlighting substantial gaps between guideline recommendations and real-world practice.
Q. Chan, J. Cegla, J. Cornel et al.· European Heart Journal· 0 citations
BACKGROUND
Evolocumab reduces major adverse cardiovascular events in randomized trials, but evidence of its effectiveness in real-world clinical practice remains limited.
METHODS
US adults with atherosclerotic cardiovascular disease who initiated evolocumab between 2017 and 2023 were identified from the Komodo Health...
Ran Jin, K. Hurwitz, N. Dhalwani et al.· Journal of the American Hear...· 0 citations
Most patients at high CV risk were not optimally managed, with low rates of LLT initiation, treatment intensification, LDL-C monitoring, and LDL-C goal attainment across 11 databases, highlighting a substantial unmet clinical need for improved guideline-based lipid management to prevent first major CV events in high-ri...
Q. Chan, J. Cegla, U. Laufs et al.· Clinical Research in Cardiol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.